Equities researchers at Guggenheim initiated coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Get Free Report) in a research note issued to investors on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $75.00 price target on the stock. Guggenheim‘s price objective points to a potential upside of 162.15% from the company’s current price.
A number of other equities research analysts have also issued reports on the stock. Evercore started coverage on shares of Lycia Therapeutics in a report on Tuesday. They set an “outperform” rating and a $43.00 price target on the stock. Wall Street Zen raised shares of Lycia Therapeutics to a “hold” rating in a research note on Saturday, October 31st. Finally, Jefferies Financial Group initiated coverage on shares of Lycia Therapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $56.00.
Get Our Latest Analysis on Lycia Therapeutics
Lycia Therapeutics Price Performance
LYCA stock opened at $28.61 on Tuesday. Lycia Therapeutics has a one year low of $22.19 and a one year high of $36.49.
Insider Transactions at Lycia Therapeutics
In other Lycia Therapeutics news, major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of Lycia Therapeutics stock in a transaction that occurred on Monday, November 2nd. The stock was purchased at an average cost of $26.95 per share, with a total value of $223,819.75. Following the purchase, the insider owned 6,858,542 shares in the company, valued at approximately $184,837,706.90. The trade was a 0.12% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders bought 2,078,749 shares of company stock valued at $38,526,342.
About Lycia Therapeutics
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
Recommended Stories
- Five stocks we like better than Lycia Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
